1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED 24
1.3.2 YEARS CONSIDERED FOR THE STUDY 25
1.4 CURRENCY 25
1.5 STAKEHOLDERS 25
1.6 LIMITATIONS OF THE CURRENT EDITION 25
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 1 RESEARCH DESIGN 27
2.1.1 SECONDARY DATA 28
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY DATA 29
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29
2.1.2.1 Key data from primary sources 29
2.2 MARKET SIZE ESTIMATION 30
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 30
2.2.1 BOTTOM-UP APPROACH 31
FIGURE 4 BPH TREATMENT MARKET: BOTTOM-UP APPROACH 31
2.2.2 GROWTH FORECAST 32
2.2.3 TOP-DOWN APPROACH 32
FIGURE 5 BPH TREATMENT MARKET: TOP-DOWN APPROACH 32
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 33
FIGURE 6 DATA TRIANGULATION METHODOLOGY 33
2.4 ASSUMPTIONS FOR THE STUDY 34
3 EXECUTIVE SUMMARY 35
FIGURE 7 BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION) 35
FIGURE 8 BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD BILLION) 36
FIGURE 9 BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION) 36
4 PREMIUM INSIGHTS 37
4.1 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW 37
FIGURE 10 INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET 37
4.2 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020) 37
FIGURE 11 DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020 37
4.3 GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET 38
FIGURE 12 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 38
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
FIGURE 13 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
5.2.1 DRIVERS 40
5.2.1.1 Increasing prevalence of benign prostatic hyperplasia 40
FIGURE 14 SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019) 40
5.2.1.2 Increasing obesity 40
5.2.1.3 Rising preference for minimally invasive surgeries 41
5.2.1.4 Investments, funds, and grants for research in BPH treatment 41
5.2.1.5 Availability of reimbursement for surgeries 42
TABLE 1 CPT CODES FOR BPH SURGERIES 42
5.2.2 RESTRAINTS 42
5.2.2.1 Side-effects associated with BPH medications 42
TABLE 2 SIDE-EFFECTS OF BPH DRUGS 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Emerging markets 43
5.2.3.2 Promising product pipeline 44
TABLE 3 PIPELINE DRUGS 44
5.2.4 CHALLENGES 44
5.2.4.1 Low awareness regarding prostate health among men 44
5.2.4.2 Product recalls in the BPH treatment market 44
TABLE 4 PRODUCT RECALLS IN THE BPH TREATMENT MARKET 45
5.3 VALUE CHAIN ANALYSIS 45
FIGURE 15 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 45
5.4 SUPPLY CHAIN ANALYSIS 46
FIGURE 16 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES 47
5.5 ECOSYSTEM ANALYSIS 47
FIGURE 17 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY 47
FIGURE 18 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET 48
5.6 REGULATORY SCENARIO 48
5.6.1 PHARMACEUTICAL INDUSTRY 48
5.6.1.1 Regulatory requirements 48
5.6.1.1.1 EU regulations 48
5.6.1.1.2 US regulations 49
5.6.2 MEDICAL DEVICES INDUSTRY 49
TABLE 5 LIST OF REGULATORY AUTHORITIES 49
5.6.2.1 Regulatory requirements 50
5.6.2.1.1 EU regulations 50
5.6.2.1.2 US regulations 51
5.7 AVERAGE SELLING PRICE TREND 51
TABLE 6 AVERAGE SELLING PRICE OF BPH DRUGS 51
TABLE 7 AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES 52
TABLE 8 AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES 52
5.8 TECHNOLOGY ANALYSIS 52
5.9 PESTLE ANALYSIS 54
5.10 COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET 55
5.11 EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019) 55
TABLE 9 BPH: COUNTRY-WISE PREVALENCE, 2019 55
6 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE 56
6.1 INTRODUCTION 57
TABLE 10 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 57
6.2 DRUG TREATMENT 57
TABLE 11 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 57
TABLE 12 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION) 58
6.2.1 ALPHA BLOCKERS 58
TABLE 13 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 58
TABLE 14 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018–2026 (USD MILLION) 59
6.2.1.1 Tamsulosin 59
6.2.1.1.1 Tamsulosin has been prescribed for BPH since 2000 59
TABLE 15 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 59
6.2.1.2 Silodosin 60
6.2.1.2.1 Benefits of silodosin and launch of generics support market growth 60
TABLE 16 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 60
6.2.1.3 Alfuzosin 60
6.2.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent 60
TABLE 17 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 61
6.2.1.4 Doxazosin 61
6.2.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since 61
TABLE 18 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 61
6.2.1.5 Other alpha blockers 62
TABLE 19 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION) 62
6.2.2 5-ALPHA REDUCTASE INHIBITORS 62
TABLE 20 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 62
TABLE 21 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION) 63
6.2.2.1 Dutasteride 63
6.2.2.1.1 Availability of generics post-patent expiry support market growth 63
TABLE 22 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION) 63
6.2.2.2 Finasteride 64
6.2.2.2.1 Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS 64
TABLE 23 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION) 64
6.2.3 OTHER DRUG CLASSES 64
TABLE 24 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION) 65
6.3 SURGICAL TREATMENT 65
TABLE 25 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 65
TABLE 26 BPH SURGICAL TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION) 66
6.3.1 TRANSURETHRAL RESECTION OF THE PROSTATE 66
6.3.1.1 TURP is the gold standard for BPH treatment 66
TABLE 27 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018–2026 (USD MILLION) 67
6.3.2 LASER SURGERY 67
6.3.2.1 Evolution in lasers and high efficacy have supported the demand for laser surgery 67
TABLE 28 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION, 2018–2026 (USD MILLION) 67
6.3.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY 68
6.3.3.1 TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference 68
TABLE 29 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018–2026 (USD MILLION) 68
6.3.4 UROLIFT THERAPY 68
6.3.4.1 Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption 68
TABLE 30 BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION, 2018–2026 (USD MILLION) 69
6.3.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE 69
6.3.5.1 Reimbursement coverage and growing preference for TUNA drive market growth 69
TABLE 31 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018–2026 (USD MILLION) 70
6.3.6 REZŪM THERAPY 70
6.3.6.1 The cost-effectiveness and efficacy of Rezūm water vapor therapy are driving demand for the procedure 70
TABLE 32 BPH SURGICAL TREATMENT MARKET FOR REZŪM THERAPY, BY REGION, 2018–2026 (USD MILLION) 71
6.3.7 PROSTATIC STENTING 71
6.3.7.1 Prostatic stenting is a temporary measure conducted under local anesthesia 71
TABLE 33 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2018–2026 (USD MILLION) 71
6.3.8 OTHER SURGERIES 72
TABLE 34 OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018–2026 (USD MILLION) 72
7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER 73
7.1 INTRODUCTION 74
TABLE 35 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 74
7.2 HOME HEALTHCARE 74
7.2.1 LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT 74
TABLE 36 BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION, 2018–2026 (USD MILLION) 75
7.3 HOSPITALS & CLINICS 75
7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT 75
TABLE 37 BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018–2026 (USD MILLION) 76
8 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION 77
8.1 INTRODUCTION 78
TABLE 38 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION) 78
8.2 NORTH AMERICA 79
FIGURE 19 NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT 79
TABLE 39 NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION) 79
TABLE 40 NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 80
TABLE 41 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 80
TABLE 42 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 80
TABLE 43 NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 81
TABLE 44 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 81
TABLE 45 NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 81
8.2.1 US 82
8.2.1.1 The US holds the largest share of the North American market 82
TABLE 46 US: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 82
TABLE 47 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 82
TABLE 48 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 83
TABLE 49 US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 83
TABLE 50 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 83
TABLE 51 US: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 84
8.2.2 CANADA 84
8.2.2.1 Rising geriatric population and product approvals to support market growth 84
TABLE 52 CANADA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 84
TABLE 53 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 85
TABLE 54 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 85
TABLE 55 CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 85
TABLE 56 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 86
TABLE 57 CANADA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 86
8.3 EUROPE 86
TABLE 58 EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 86
TABLE 59 EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 87
TABLE 60 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 87
TABLE 61 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 87
TABLE 62 EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 87
TABLE 63 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 88
TABLE 64 EUROPE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 88
8.3.1 GERMANY 88
8.3.1.1 Increasing healthcare expenditure to support German market growth 88
TABLE 65 GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 89
TABLE 66 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 89
TABLE 67 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 89
TABLE 68 GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 89
TABLE 69 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 90
TABLE 70 GERMANY: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 90
8.3.2 UK 90
8.3.2.1 Availability of innovative treatment options to drive the market in the UK 90
TABLE 71 UK: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 91
TABLE 72 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 91
TABLE 73 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 91
TABLE 74 UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 91
TABLE 75 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 92
TABLE 76 UK: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 92
8.3.3 FRANCE 92
8.3.3.1 Rising geriatric population to accelerate the growth of the market 92
TABLE 77 FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 93
TABLE 78 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 93
TABLE 79 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 93
TABLE 80 FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 93
TABLE 81 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 94
TABLE 82 FRANCE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 94
8.3.4 REST OF EUROPE 94
TABLE 83 ROE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 95
TABLE 84 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 95
TABLE 85 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 95
TABLE 86 ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 95
TABLE 87 ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 96
TABLE 88 ROE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 96
8.4 ASIA PACIFIC 97
FIGURE 20 ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT 97
TABLE 89 ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION) 98
TABLE 90 ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 98
TABLE 91 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 98
TABLE 92 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 99
TABLE 93 ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 99
TABLE 94 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 99
TABLE 95 ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 100
8.4.1 JAPAN 100
8.4.1.1 Japan holds the largest share of the APAC market 100
TABLE 96 JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 100
TABLE 97 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 101
TABLE 98 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 101
TABLE 99 JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 101
TABLE 100 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 102
TABLE 101 JAPAN: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 102
8.4.2 CHINA 102
8.4.2.1 Increasing obese population to support market growth 102
TABLE 102 CHINA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 103
TABLE 103 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 103
TABLE 104 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 103
TABLE 105 CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 104
TABLE 106 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 104
TABLE 107 CHINA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 104
8.4.3 INDIA 105
8.4.3.1 Rising prevalence of obesity to accelerate market growth in India 105
TABLE 108 INDIA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 105
TABLE 109 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 105
TABLE 110 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 105
TABLE 111 INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 106
TABLE 112 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 106
TABLE 113 INDIA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 106
8.4.4 REST OF ASIA PACIFIC 107
TABLE 114 ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 107
TABLE 115 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 107
TABLE 116 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 108
TABLE 117 ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 108
TABLE 118 ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 108
TABLE 119 ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 109
8.5 REST OF THE WORLD 109
TABLE 120 ROW: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 109
TABLE 121 ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 110
TABLE 122 ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION) 110
TABLE 123 ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION) 110
TABLE 124 ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION) 111
TABLE 125 ROW: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION) 111
9 COMPETITIVE LANDSCAPE & COMPANY PROFILES 112
9.1 COMPETITIVE LANDSCAPE 112
9.1.1 OVERVIEW 112
FIGURE 21 KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017–JANUARY 2021 112
FIGURE 22 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021 113
9.1.2 MARKET SHARE ANALYSIS, 2019 114
9.1.2.1 BPH Drug Treatment Market Share Analysis, 2019 114
FIGURE 23 BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019 114
9.1.2.2 BPH Surgical Treatment Market Share Analysis, 2019 115
FIGURE 24 BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019 115
9.1.3 COMPETITIVE SCENARIO 115
9.1.3.1 Product launches and approvals 115
TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017−JANUARY 2021 116
9.1.3.2 Acquisitions 116
TABLE 127 KEY ACQUISITIONS, JANUARY 2017−JANUARY 2021 116
9.1.3.3 Agreements and collaborations 117
TABLE 128 KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017−JANUARY 2021 117
9.1.3.4 Expansions 117
TABLE 129 KEY EXPANSIONS, JANUARY 2017−JANUARY 2021 117
9.1.3.5 Other developments 117
TABLE 130 OTHER DEVELOPMENTS, JANUARY 2017−JANUARY 2021 117
9.1.4 COMPANY EVALUATION MATRIX 118
9.1.4.1 Stars 118
9.1.4.2 Emerging Leaders 118
9.1.4.3 Pervasive Companies 118
9.1.4.4 Participants 118
FIGURE 25 BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019 119
9.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES) 120
9.1.5.1 Progressive Companies 120
9.1.5.2 Starting Blocks 120
9.1.5.3 Responsive Companies 120
9.1.5.4 Dynamic Companies 120
FIGURE 26 BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019 121
9.2 COMPANY PROFILES 122
(Business overview, Products offered, Recent Developments, MNM view)*
9.2.1 GLAXOSMITHKLINE 122
FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019) 122
9.2.2 ASTELLAS PHARMA 124
FIGURE 28 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019) 124
9.2.3 MERCK 126
FIGURE 29 MERCK: COMPANY SNAPSHOT (2019) 126
9.2.4 ELI LILLY AND COMPANY 128
FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019) 128
9.2.5 TELEFLEX INCORPORATED 130
FIGURE 31 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019) 130
9.2.6 ABBOTT LABORATORIES 132
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 132
9.2.7 BOSTON SCIENTIFIC CORPORATION 133
FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019) 133
9.2.8 PFIZER 135
FIGURE 34 PFIZER: COMPANY SNAPSHOT (2019) 135
9.2.9 OLYMPUS CORPORATION 136
FIGURE 35 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019) 136
9.2.10 ALEMBIC 138
FIGURE 36 ALEMBIC: COMPANY SNAPSHOT (2019) 138
9.2.11 ASAHI KASEI CORPORATION 139
FIGURE 37 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019) 139
9.2.12 ALLERGAN 141
FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019) 141
9.2.13 COLOPLAST GROUP 142
FIGURE 39 COLOPLAST GROUP: COMPANY SNAPSHOT (2020) 142
9.2.14 IPG PHOTONICS CORPORATION 144
FIGURE 40 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019) 144
9.2.15 KARL STORZ SE & CO. KG 145
9.2.16 RICHARD WOLF GMBH 145
9.2.17 LUMENIS LTD. 146
9.2.18 UNILAB, INC. 146
9.2.19 PHAREX HEALTH CORP 147
9.2.20 BIOLITEC AG 147
9.2.21 UROLOGIX, LLC. 148
9.2.22 ADVIN HEALTH CARE 148
9.2.23 MEDIFOCUS INC. 148
9.2.24 ASCLEPION LASER TECHNOLOGIES GMBH 148
9.2.25 PNN MEDICAL A/S 148
9.2.26 SURGICAL LASERS INC. 149
9.2.27 QUANTA SYSTEM 149
9.2.28 ALLIUM LTD 149
9.2.29 SRS MEDICAL 149
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
10 APPENDIX 150
10.1 INDUSTRY INSIGHTS 150
10.2 DISCUSSION GUIDE 151
10.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 155
10.4 AVAILABLE CUSTOMIZATIONS 157
10.5 RELATED REPORTS 157
10.6 AUTHOR DETAILS 158
世界の前立腺肥大症治療市場（～2026年）：種類別[薬剤（アルファ遮断薬（タムスロシン、ドキサゾシン）、5-アルファ還元酵素阻害薬（フィナステリド、デュタステリド）、外科的治療（TURP、TUMT、TUNA]、エンドユーザー別（病院） |
| 【英語タイトル】Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026 | |
 | ・商品コード：MD7836 ・発行会社（調査会社）：MarketsandMarkets ・発行日：2021年2月11日 ・ページ数：154 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内） ・調査対象地域：グローバル ・産業分野：医療 |
| Single User（1名様閲覧） | USD4,950 ⇒換算￥722,700 | 見積依頼/購入/質問フォーム |
| Multi User (Five User) | USD6,650 ⇒換算￥970,900 | 見積依頼/購入/質問フォーム |
| Corporate License (全社内共有可) | USD8,150 ⇒換算￥1,189,900 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| マーケッツアンドマーケッツ社は、世界の前立腺肥大症治療市場規模が2021年108億ドルから2026年141億ドルまで、年平均5.3%成長すると予測しています。本調査レポートでは、前立腺肥大症治療の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（投薬治療、外科的治療）分析、エンドユーザー別（在宅医療、病院・診療所）分析、地域別分析、市場シェア分析などを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・前立腺肥大症治療の世界市場規模：種類別（投薬治療、外科的治療） ・前立腺肥大症治療の世界市場規模：エンドユーザー別（在宅医療、病院・診療所） ・前立腺肥大症治療の世界市場規模：地域別 ・市場シェア分析 |
“The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.”
The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment. Also, the emerging markets and promising product pipeline is anticipated to offer an opportunity for the growth of the market during the forecast period.
“Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.”
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.
“Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.”
Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.
“North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.”
On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (33%), Europe (24%), AsiaPacific (27%), and Rest of the World (16%)
The some of the major players operating in this market are GlaxoSmithKline plc. (UK), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Eli Lilly and Company (US), and Teleflex Incorporated (US).
List of Companies Profiled in the Report
• Boston Scientific Corporation (US)
• Coloplast Group (Denmark)
• Teleflex Incorporated (US)
• Olympus Corporation (Japan)
• GlaxoSmithKline PLC (UK)
• Eli Lilly (US)
• Pfizer, Inc. (US)
• Abbott (US)
• Asahi Kasei Corporation (Japan)
• Merck & Co., Inc. (US)
• Astellas Pharma Inc. (Japan)
• Allergan plc (Ireland)
• Alembic (India)
• IPG Photonics Corporation (US)
• Richard Wolf GmbH (Germany)
• Unilab, Inc. (Philippines)
• Pharex Health Corporation (Philippines)
• Biolitec AG (Austria)
• Urologix, LLC (US)
• Advin Health Care (India)
• Medifocus, Inc. (Canada)
• Asclepion Laser Technologies GmbH (Germany)
• Pnn Medical A/S (Denmark)
• Surgical Lasers Inc. (Canada)
• Quanta Systems (Italy)
• Allium Ltd. (Israel)
• Lumenis Ltd. (Israel)
• KARL STORZ SE & Co. KG (Germany)
• SRS Medical (US).
Research Coverage
This report studies the benign prostatic hyperplasia treatment market based on type, end user and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total benign prostatic hyperplasia treatment market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on benign prostatic hyperplasia treatment offered by the top 29 players in the benign prostatic hyperplasia treatment market. The report analyzes the benign prostatic hyperplasia treatment market type, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the benign prostatic hyperplasia treatment market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the benign prostatic hyperplasia treatment market
Frequently asked questions
• What are the growth opportunities in the benign prostatic hyperplasia treatment market across major regions in the future?
• Which type of drug is expected to hold the largest share in the benign prostatic hyperplasia treatment market?
• Which form of surgery has been widely used in BPH treatment?
• Which region has a well-developed benign prostatic hyperplasia treatment market?
• What is the impact of COVID-19 on benign prostatic hyperplasia treatment market?
| ★調査レポート[世界の前立腺肥大症治療市場（～2026年）：種類別[薬剤（アルファ遮断薬（タムスロシン、ドキサゾシン）、5-アルファ還元酵素阻害薬（フィナステリド、デュタステリド）、外科的治療（TURP、TUMT、TUNA]、エンドユーザー別（病院）] (コード：MD7836)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の前立腺肥大症治療市場（～2026年）：種類別[薬剤（アルファ遮断薬（タムスロシン、ドキサゾシン）、5-アルファ還元酵素阻害薬（フィナステリド、デュタステリド）、外科的治療（TURP、TUMT、TUNA]、エンドユーザー別（病院）]についてメールでお問い合わせ |
